45 related articles for article (PubMed ID: 12549627)
1. Novel 3,9-Disubstituted Acridines with Strong Inhibition Activity against Topoisomerase I: Synthesis, Biological Evaluation and Molecular Docking Study.
Krochtová K; Halečková A; Janovec L; Blizniaková M; Kušnírová K; Kožurková M
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770975
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerases as molecular targets for anticancer drugs.
Buzun K; Bielawska A; Bielawski K; Gornowicz A
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1781-1799. PubMed ID: 32975138
[TBL] [Abstract][Full Text] [Related]
3. Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities.
Lemke K; Wojciechowski M; Laine W; Bailly C; Colson P; Baginski M; Larsen AK; Skladanowski A
Nucleic Acids Res; 2005; 33(18):6034-47. PubMed ID: 16254080
[TBL] [Abstract][Full Text] [Related]
4. Antitumor polycyclic acridines. Part 16. Triplex DNA as a target for DNA-binding polycyclic acridine derivatives.
Missailidis S; Modi C; Trapani V; Laughton CA; Stevens MF
Oncol Res; 2005; 15(2):95-105. PubMed ID: 16119007
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
Kim MY; Duan W; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Feb; 46(4):571-83. PubMed ID: 12570378
[TBL] [Abstract][Full Text] [Related]
7. Photochemical electrocyclisation of 3-vinylindoles to pyrido[2,3-a]-, pyrido[4,3-a]- and thieno[2,3-a]-carbazoles: design, synthesis, DNA binding and antitumor cell cytotoxicity.
Lemster T; Pindur U; Lenglet G; Depauw S; Dassi C; David-Cordonnier MH
Eur J Med Chem; 2009 Aug; 44(8):3235-52. PubMed ID: 19386396
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
9. Antitumor polycyclic acridines. Part 12. Physical and biological properties of 8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide: a lead compound in anticancer drug design.
Missailidis S; Stanslas J; Modi C; Ellis MJ; Robins RA; Laughton CA; Stevens MF
Oncol Res; 2002; 13(3):175-89. PubMed ID: 12549627
[TBL] [Abstract][Full Text] [Related]
10. Emerging DNA topisomerase inhibitors as anticancer drugs.
Denny WA
Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139
[TBL] [Abstract][Full Text] [Related]
11. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
12. Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
Pindur U; Lemster T
Pharmazie; 1998 Feb; 53(2):79-86. PubMed ID: 9540103
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
